Dexmedetomidine and Netrin-1 Combination Therapy Inhibits Endoplasmic Reticulum Stress by Regulating the ERK5/MEF2A Pathway to Attenuate Cerebral Ischemia Injury
The complexity of hard-to-treat diseases such as ischemic stroke strongly undermines the therapeutic potential of available treatment options. Therefore, current developments have gently shifted from a focus on monotherapy to combined or multiple therapies. Both dexmedetomidine and Netrin-1 have ant...
Saved in:
| Published in | Frontiers in neuroscience Vol. 15; p. 641345 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
Frontiers Research Foundation
28.01.2021
Frontiers Media S.A |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The complexity of hard-to-treat diseases such as ischemic stroke strongly undermines the therapeutic potential of available treatment options. Therefore, current developments have gently shifted from a focus on monotherapy to combined or multiple therapies. Both dexmedetomidine and Netrin-1 have anti-neuronal apoptosis effects, but the mechanism is still unclear. The study aimed to estimate the efficacy of dexmedetomidine and Netrin-1 combination therapy against ERS-induced apoptosis after cerebral ischemia injury
in vivo
and
in vitro
, and whether the mechanism is related to the ERK5/MEF2A pathway. Adult male Sprague-Dawley rats were subjected to middle cerebral artery occlusion (MCAO)
in vivo
, 90 min ischemia and 24 h reperfusion. The hippocampus slices used to establish oxygen-glucose deprivation (OGD) injury model
in vitro
. Neterin-1 and Dexmedetomidine were pretreated and post-treated, respectively, before and after the model establishment. MEF2A knockdown was performed by microinjection of AAV9-MEF2A RNAi vector. Orthodromic population spike (OPS) at the end of reoxygenation were recorded. Neurobehavioral tests, TTC staining, Nissl staining, TUNEL staining were performed to assess the effect of the drugs. The expression of CHOP, GRP78, MEF2A, ERK5, and p-ERK5 were investigated by Western blot and immunofluorescence staining. Neurological deficit score, infarct volume, the expression of GRP78, CHOP, and neural apoptotic rate of MCAO group increased markedly. Combination of dexmedetomidine and Netrin-1 resulted in lower infarct volumes and fewer neurological impairments, higher OPS recovery rate, and less damaged and apoptotic cells after cerebral ischemia injury. Furthermore, expression levels of GRP78 and CHOP decreased in the combination therapy group, and it was more effective than the single drug group. Meanwhile, Combination of dexmedetomidine and Netrin-1 increased MEF2A expression and promoted ERK5 phosphorylation. However, the protective effect of dexmedetomidine combined with Netrin-1 in improving neurological function was significantly eliminated by pre-knockdown MEF2A. The neuroprotective effects of dexmedetomidine combined with Netrin on cerebral ischemia-reperfusion injury and hippocampal hypoxia injury in terms of ERS. The synergistic effect of combination therapy is related to the activation of ERK5/MEF2A signaling pathway. |
|---|---|
| AbstractList | The complexity of hard-to-treat diseases such as ischemic stroke strongly undermines the therapeutic potential of available treatment options. Therefore, current developments have gently shifted from a focus on monotherapy to combined or multiple therapies. Both dexmedetomidine and Netrin-1 have anti-neuronal apoptosis effects, but the mechanism is still unclear. The study aimed to estimate the efficacy of dexmedetomidine and Netrin-1 combination therapy against ERS-induced apoptosis after cerebral ischemia injury in vivo and in vitro, and whether the mechanism is related to the ERK5/MEF2A pathway. Adult male Sprague-Dawley rats were subjected to middle cerebral artery occlusion (MCAO) in vivo, 90 min ischemia and 24 h reperfusion. The hippocampus slices used to establish oxygen-glucose deprivation (OGD) injury model in vitro. Neterin-1 and Dexmedetomidine were pretreated and post-treated, respectively, before and after the model establishment. MEF2A knockdown was performed by microinjection of AAV9-MEF2A RNAi vector. Orthodromic population spike (OPS) at the end of reoxygenation were recorded. Neurobehavioral tests, TTC staining, Nissl staining, TUNEL staining were performed to assess the effect of the drugs. The expression of CHOP, GRP78, MEF2A, ERK5, and p-ERK5 were investigated by Western blot and immunofluorescence staining. Neurological deficit score, infarct volume, the expression of GRP78, CHOP, and neural apoptotic rate of MCAO group increased markedly. Combination of dexmedetomidine and Netrin-1 resulted in lower infarct volumes and fewer neurological impairments, higher OPS recovery rate, and less damaged and apoptotic cells after cerebral ischemia injury. Furthermore, expression levels of GRP78 and CHOP decreased in the combination therapy group, and it was more effective than the single drug group. Meanwhile, Combination of dexmedetomidine and Netrin-1 increased MEF2A expression and promoted ERK5 phosphorylation. However, the protective effect of dexmedetomidine combined with Netrin-1 in improving neurological function was significantly eliminated by pre-knockdown MEF2A. The neuroprotective effects of dexmedetomidine combined with Netrin on cerebral ischemia-reperfusion injury and hippocampal hypoxia injury in terms of ERS. The synergistic effect of combination therapy is related to the activation of ERK5/MEF2A signaling pathway. The complexity of hard-to-treat diseases such as ischemic stroke strongly undermines the therapeutic potential of available treatment options. Therefore, current developments have gently shifted from a focus on monotherapy to combined or multiple therapies. Both dexmedetomidine and Netrin-1 have anti-neuronal apoptosis effects, but the mechanism is still unclear. The study aimed to estimate the efficacy of dexmedetomidine and Netrin-1 combination therapy against ERS-induced apoptosis after cerebral ischemia injury in vivo and in vitro , and whether the mechanism is related to the ERK5/MEF2A pathway. Adult male Sprague-Dawley rats were subjected to middle cerebral artery occlusion (MCAO) in vivo , 90 min ischemia and 24 h reperfusion. The hippocampus slices used to establish oxygen-glucose deprivation (OGD) injury model in vitro . Neterin-1 and Dexmedetomidine were pretreated and post-treated, respectively, before and after the model establishment. MEF2A knockdown was performed by microinjection of AAV9-MEF2A RNAi vector. Orthodromic population spike (OPS) at the end of reoxygenation were recorded. Neurobehavioral tests, TTC staining, Nissl staining, TUNEL staining were performed to assess the effect of the drugs. The expression of CHOP, GRP78, MEF2A, ERK5, and p-ERK5 were investigated by Western blot and immunofluorescence staining. Neurological deficit score, infarct volume, the expression of GRP78, CHOP, and neural apoptotic rate of MCAO group increased markedly. Combination of dexmedetomidine and Netrin-1 resulted in lower infarct volumes and fewer neurological impairments, higher OPS recovery rate, and less damaged and apoptotic cells after cerebral ischemia injury. Furthermore, expression levels of GRP78 and CHOP decreased in the combination therapy group, and it was more effective than the single drug group. Meanwhile, Combination of dexmedetomidine and Netrin-1 increased MEF2A expression and promoted ERK5 phosphorylation. However, the protective effect of dexmedetomidine combined with Netrin-1 in improving neurological function was significantly eliminated by pre-knockdown MEF2A. The neuroprotective effects of dexmedetomidine combined with Netrin on cerebral ischemia-reperfusion injury and hippocampal hypoxia injury in terms of ERS. The synergistic effect of combination therapy is related to the activation of ERK5/MEF2A signaling pathway. The complexity of hard-to-treat diseases such as ischemic stroke strongly undermines the therapeutic potential of available treatment options. Therefore, current developments have gently shifted from a focus on monotherapy to combined or multiple therapies. Both dexmedetomidine and netrin-1 have anti-neuronal apoptosis effects, but the mechanism is still unclear. The study aimed to estimate the efficacy of dexmedetomidine and Netrin-1 combination therapy against ERS-induced apoptosis after cerebral ischemia injury in vivo and in vitro, and whether the mechanism is related to the ERK5/MEF2A pathway. Adult male Sprague-Dawley rats were subjected to middle cerebral artery occlusion (MCAO) in vivo, 90 min ischemia and 24 h reperfusion. The hippocampus slices used to establish oxygen-glucose deprivation (OGD) injury model in vitro. Neterin-1 and Dexmedetomidine were pretreated and post-treated respectively before and after the model establishment. MEF2A knockdown was performed by microinjection of AAV9-MEF2A RNAi vector. Orthodromic population spike (OPS) at the end of reoxygenation were recorded. Neurobehavioral tests, TTC staining, Nissl staining, TUNEL staining were performed to assess the effect of the drugs. The expression of CHOP, GRP78, MEF2A, ERK5, p-ERK5 were investigated by Western blot and immunofluorescence staining. Neurological deficit score, infarct volume, the expression of GRP78, CHOP, and neural apoptotic rate of MCAO group increased markedly. Combination of dexmedetomidine and Netrin-1 resulted in lower infarct volumes and fewer neurological impairments, higher OPS recovery rate, and less damaged and apoptotic cells after cerebral ischemia injury. Furthermore, expression levels of GRP78 and CHOP decreased in the combination therapy group, and it was more effective than the single drug group. Meanwhile, Combination of dexmedetomidine and Netrin-1 increased MEF2A expression and promoted ERK5 phosphorylation. However, the protective effect of dexmedetomidine combined with Netrin-1 in improving neurological function was significantly eliminated by pre-knockdown MEF2A. The neuroprotective effects of dexmedetomidine combined with Netrin on cerebral ischemia-reperfusion injury and hippocampal hypoxia injury in terms of ERS. The synergistic effect of combination therapy is related to the activation of ERK5/MEF2A signaling pathway. The complexity of hard-to-treat diseases such as ischemic stroke strongly undermines the therapeutic potential of available treatment options. Therefore, current developments have gently shifted from a focus on monotherapy to combined or multiple therapies. Both dexmedetomidine and Netrin-1 have anti-neuronal apoptosis effects, but the mechanism is still unclear. The study aimed to estimate the efficacy of dexmedetomidine and Netrin-1 combination therapy against ERS-induced apoptosis after cerebral ischemia injury in vivo and in vitro, and whether the mechanism is related to the ERK5/MEF2A pathway. Adult male Sprague-Dawley rats were subjected to middle cerebral artery occlusion (MCAO) in vivo, 90 min ischemia and 24 h reperfusion. The hippocampus slices used to establish oxygen-glucose deprivation (OGD) injury model in vitro. Neterin-1 and Dexmedetomidine were pretreated and post-treated, respectively, before and after the model establishment. MEF2A knockdown was performed by microinjection of AAV9-MEF2A RNAi vector. Orthodromic population spike (OPS) at the end of reoxygenation were recorded. Neurobehavioral tests, TTC staining, Nissl staining, TUNEL staining were performed to assess the effect of the drugs. The expression of CHOP, GRP78, MEF2A, ERK5, and p-ERK5 were investigated by Western blot and immunofluorescence staining. Neurological deficit score, infarct volume, the expression of GRP78, CHOP, and neural apoptotic rate of MCAO group increased markedly. Combination of dexmedetomidine and Netrin-1 resulted in lower infarct volumes and fewer neurological impairments, higher OPS recovery rate, and less damaged and apoptotic cells after cerebral ischemia injury. Furthermore, expression levels of GRP78 and CHOP decreased in the combination therapy group, and it was more effective than the single drug group. Meanwhile, Combination of dexmedetomidine and Netrin-1 increased MEF2A expression and promoted ERK5 phosphorylation. However, the protective effect of dexmedetomidine combined with Netrin-1 in improving neurological function was significantly eliminated by pre-knockdown MEF2A. The neuroprotective effects of dexmedetomidine combined with Netrin on cerebral ischemia-reperfusion injury and hippocampal hypoxia injury in terms of ERS. The synergistic effect of combination therapy is related to the activation of ERK5/MEF2A signaling pathway.The complexity of hard-to-treat diseases such as ischemic stroke strongly undermines the therapeutic potential of available treatment options. Therefore, current developments have gently shifted from a focus on monotherapy to combined or multiple therapies. Both dexmedetomidine and Netrin-1 have anti-neuronal apoptosis effects, but the mechanism is still unclear. The study aimed to estimate the efficacy of dexmedetomidine and Netrin-1 combination therapy against ERS-induced apoptosis after cerebral ischemia injury in vivo and in vitro, and whether the mechanism is related to the ERK5/MEF2A pathway. Adult male Sprague-Dawley rats were subjected to middle cerebral artery occlusion (MCAO) in vivo, 90 min ischemia and 24 h reperfusion. The hippocampus slices used to establish oxygen-glucose deprivation (OGD) injury model in vitro. Neterin-1 and Dexmedetomidine were pretreated and post-treated, respectively, before and after the model establishment. MEF2A knockdown was performed by microinjection of AAV9-MEF2A RNAi vector. Orthodromic population spike (OPS) at the end of reoxygenation were recorded. Neurobehavioral tests, TTC staining, Nissl staining, TUNEL staining were performed to assess the effect of the drugs. The expression of CHOP, GRP78, MEF2A, ERK5, and p-ERK5 were investigated by Western blot and immunofluorescence staining. Neurological deficit score, infarct volume, the expression of GRP78, CHOP, and neural apoptotic rate of MCAO group increased markedly. Combination of dexmedetomidine and Netrin-1 resulted in lower infarct volumes and fewer neurological impairments, higher OPS recovery rate, and less damaged and apoptotic cells after cerebral ischemia injury. Furthermore, expression levels of GRP78 and CHOP decreased in the combination therapy group, and it was more effective than the single drug group. Meanwhile, Combination of dexmedetomidine and Netrin-1 increased MEF2A expression and promoted ERK5 phosphorylation. However, the protective effect of dexmedetomidine combined with Netrin-1 in improving neurological function was significantly eliminated by pre-knockdown MEF2A. The neuroprotective effects of dexmedetomidine combined with Netrin on cerebral ischemia-reperfusion injury and hippocampal hypoxia injury in terms of ERS. The synergistic effect of combination therapy is related to the activation of ERK5/MEF2A signaling pathway. The complexity of hard-to-treat diseases such as ischemic stroke strongly undermines the therapeutic potential of available treatment options. Therefore, current developments have gently shifted from a focus on monotherapy to combined or multiple therapies. Both dexmedetomidine and Netrin-1 have anti-neuronal apoptosis effects, but the mechanism is still unclear. The study aimed to estimate the efficacy of dexmedetomidine and Netrin-1 combination therapy against ERS-induced apoptosis after cerebral ischemia injury and , and whether the mechanism is related to the ERK5/MEF2A pathway. Adult male Sprague-Dawley rats were subjected to middle cerebral artery occlusion (MCAO) , 90 min ischemia and 24 h reperfusion. The hippocampus slices used to establish oxygen-glucose deprivation (OGD) injury model . Neterin-1 and Dexmedetomidine were pretreated and post-treated, respectively, before and after the model establishment. MEF2A knockdown was performed by microinjection of AAV9-MEF2A RNAi vector. Orthodromic population spike (OPS) at the end of reoxygenation were recorded. Neurobehavioral tests, TTC staining, Nissl staining, TUNEL staining were performed to assess the effect of the drugs. The expression of CHOP, GRP78, MEF2A, ERK5, and p-ERK5 were investigated by Western blot and immunofluorescence staining. Neurological deficit score, infarct volume, the expression of GRP78, CHOP, and neural apoptotic rate of MCAO group increased markedly. Combination of dexmedetomidine and Netrin-1 resulted in lower infarct volumes and fewer neurological impairments, higher OPS recovery rate, and less damaged and apoptotic cells after cerebral ischemia injury. Furthermore, expression levels of GRP78 and CHOP decreased in the combination therapy group, and it was more effective than the single drug group. Meanwhile, Combination of dexmedetomidine and Netrin-1 increased MEF2A expression and promoted ERK5 phosphorylation. However, the protective effect of dexmedetomidine combined with Netrin-1 in improving neurological function was significantly eliminated by pre-knockdown MEF2A. The neuroprotective effects of dexmedetomidine combined with Netrin on cerebral ischemia-reperfusion injury and hippocampal hypoxia injury in terms of ERS. The synergistic effect of combination therapy is related to the activation of ERK5/MEF2A signaling pathway. |
| Author | Li, Jia Li, Yan Yin, Jiang-Wen Zuo, Yun-Xia Ren, Yi-Min Wang, Rui-Xue Wang, Sheng |
| AuthorAffiliation | 1 Department of Anesthesiology, West China Hospital of Sichuan University , Chengdu , China 4 Department of Anesthesiology, The Affiliated Hospital of Guizhou Medical University , Guiyang , China 5 Department of Anesthesiology, First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China , Hefei , China 2 Laboratory of Anesthesia and Critical Care Medicine, Translational Neuroscience Center, West China Hospital of Sichuan University , Chengdu , China 3 Department of Anesthesiology, First Affiliated Hospital, School of Medicine, Shihezi University , Shihezi , China |
| AuthorAffiliation_xml | – name: 1 Department of Anesthesiology, West China Hospital of Sichuan University , Chengdu , China – name: 4 Department of Anesthesiology, The Affiliated Hospital of Guizhou Medical University , Guiyang , China – name: 3 Department of Anesthesiology, First Affiliated Hospital, School of Medicine, Shihezi University , Shihezi , China – name: 5 Department of Anesthesiology, First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China , Hefei , China – name: 2 Laboratory of Anesthesia and Critical Care Medicine, Translational Neuroscience Center, West China Hospital of Sichuan University , Chengdu , China |
| Author_xml | – sequence: 1 givenname: Jiang-Wen surname: Yin fullname: Yin, Jiang-Wen – sequence: 2 givenname: Jia surname: Li fullname: Li, Jia – sequence: 3 givenname: Yi-Min surname: Ren fullname: Ren, Yi-Min – sequence: 4 givenname: Yan surname: Li fullname: Li, Yan – sequence: 5 givenname: Rui-Xue surname: Wang fullname: Wang, Rui-Xue – sequence: 6 givenname: Sheng surname: Wang fullname: Wang, Sheng – sequence: 7 givenname: Yun-Xia surname: Zuo fullname: Zuo, Yun-Xia |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33584197$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1UstuEzEUtVARbQMfwAZZYsMmqR_jeWyQqpBCRHmoFImd5fHcyTiasVPbA-Rz-FOcpEVtJVa2rs85vufec4qOrLOA0EtKZpyX1VlrjQ0zRhid5RnlmXiCTmies2km-I-je_djdBrCmpCclRl7ho45F2VGq-IE_XkHvwdoILrBNMYCVrbBnyF6Y6cUz91QG6uicRZfd-DVZouXtjO1iQEvbOM2vQqD0fgKotFjPw74W_QQAq63qbYa-8S1Kxw7wIurj-Ls0-KCneOvKna_1BZHh89jBDuqCHgOHmqverwMuoPBqPTTevTb5-hpq_oAL27PCfp-sbief5hefnm_nJ9fTnVW8TgVvBW1qAtelqoFXRPekpzkui7KhnOmi5bnLCsKkSuhSMlUBbmgLXACGSubik_Q8qDbOLWWG28G5bfSKSP3BedXUvnksgdJCYFGFzRjOckYqauWVxo4E7ShijCWtN4etDZjnaarwcbk7IHowxdrOrlyP2VRFjmvyiTw5lbAu5sRQpSDCRr6XllwY5AsK6vkLu03QV8_gq7d6G0a1Q7FOBUkRWCCXt3v6F8rd0lIgOIA0N6F4KGV2sT95lODpk-e5S5zcp85ucucPGQuMekj5p34_zl_AZje3AU |
| CitedBy_id | crossref_primary_10_1002_kjm2_12879 crossref_primary_10_1016_j_neuroscience_2023_10_020 crossref_primary_10_2174_1570159X20666220302150723 crossref_primary_10_3233_THC_231357 crossref_primary_10_1007_s12035_024_04398_9 crossref_primary_10_4196_kjpp_2024_28_3_239 crossref_primary_10_3389_fphar_2024_1437445 crossref_primary_10_1080_07853890_2023_2209735 crossref_primary_10_1080_21655979_2022_2078557 crossref_primary_10_1007_s12031_023_02135_w crossref_primary_10_1111_cbdd_70022 crossref_primary_10_1007_s11064_024_04169_x crossref_primary_10_3390_biomedicines12040812 crossref_primary_10_1155_2021_4968300 crossref_primary_10_1016_j_intimp_2022_109057 crossref_primary_10_14336_AD_2022_0825 crossref_primary_10_3389_fcell_2021_742049 |
| Cites_doi | 10.1007/s12035-016-0199-2 10.1136/neurintsurg-2019-014873 10.1002/dneu.22791 10.1186/s12974-018-1351-x 10.1007/s007020170071 10.1016/j.nbd.2011.09.012 10.1016/s0140-6736(16)30580-3 10.1016/j.neuroscience.2008.08.015 10.1016/j.lfs.2006.06.041 10.1161/circulationaha.112.000936 10.1097/00000542-199412000-00017 10.1016/j.ceca.2017.05.003 10.1213/01.ane.0000281075.77316.98 10.1007/s12031-017-0902-4 10.1016/j.pneurobio.2020.101905 10.1038/nprot.2007.359 10.14348/molcells.2017.2296 10.1002/adhm.202001571 10.3389/fnins.2017.00700 10.1161/STROKEAHA.108.531632 10.1046/j.1471-4159.1997.69062538.x 10.1007/s12264-010-6024-4 10.3389/fnins.2019.00321 10.1016/j.bbamcr.2011.06.015 10.1016/j.bcp.2020.114337 10.1016/j.tibs.2018.06.005 10.1007/s10753-019-01082-2 10.1016/j.cellsig.2011.01.006 10.1016/j.biopha.2016.09.075 10.1016/j.biopha.2018.11.143 10.3389/fneur.2017.00556 10.1016/S1474-4422(19)30415-6 10.18632/aging.102404 10.1016/s0140-6736(20)30631-0 |
| ContentType | Journal Article |
| Copyright | Copyright © 2021 Yin, Li, Ren, Li, Wang, Wang and Zuo. 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Copyright © 2021 Yin, Li, Ren, Li, Wang, Wang and Zuo. 2021 Yin, Li, Ren, Li, Wang, Wang and Zuo |
| Copyright_xml | – notice: Copyright © 2021 Yin, Li, Ren, Li, Wang, Wang and Zuo. – notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Copyright © 2021 Yin, Li, Ren, Li, Wang, Wang and Zuo. 2021 Yin, Li, Ren, Li, Wang, Wang and Zuo |
| DBID | AAYXX CITATION NPM 3V. 7XB 88I 8FE 8FH 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO GNUQQ HCIFZ LK8 M2P M7P PHGZM PHGZT PIMPY PKEHL PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA |
| DOI | 10.3389/fnins.2021.641345 |
| DatabaseName | CrossRef PubMed ProQuest Central (Corporate) ProQuest Central (purchase pre-March 2016) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central ProQuest Natural Science Collection ProQuest One ProQuest Central Korea ProQuest Central Student SciTech Premium Collection Biological Sciences Science Database Biological Science Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Central (New) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition Biological Science Database ProQuest SciTech Collection ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic PubMed CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Anatomy & Physiology |
| EISSN | 1662-453X |
| ExternalDocumentID | oai_doaj_org_article_100edc714260420b9f39ce3251d1a022 PMC7876398 33584197 10_3389_fnins_2021_641345 |
| Genre | Journal Article |
| GroupedDBID | --- 29H 2WC 53G 5GY 5VS 88I 8FE 8FH 9T4 AAFWJ AAYXX ABUWG ACGFO ACGFS ACXDI ADRAZ AEGXH AENEX AFKRA AFPKN AIAGR ALMA_UNASSIGNED_HOLDINGS AZQEC BBNVY BENPR BHPHI BPHCQ CCPQU CITATION CS3 DIK DU5 DWQXO E3Z EBS EJD EMOBN F5P FRP GNUQQ GROUPED_DOAJ GX1 HCIFZ HYE KQ8 LK8 M2P M48 M7P O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC RNS RPM W2D C1A NPM PQGLB 3V. 7XB 8FK PKEHL PQEST PQUKI PRINS Q9U 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c493t-53f5b5b7388afecb03f0606cb78d332c7f36247756a5a082a9e651fe30e428d93 |
| IEDL.DBID | M48 |
| ISSN | 1662-453X 1662-4548 |
| IngestDate | Wed Aug 27 01:25:33 EDT 2025 Thu Aug 21 14:11:26 EDT 2025 Fri Jul 11 07:27:31 EDT 2025 Fri Jul 25 11:43:38 EDT 2025 Mon Jul 21 06:06:50 EDT 2025 Tue Jul 01 01:39:18 EDT 2025 Thu Apr 24 22:59:12 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | cerebral ischemia/reperfusion apoptosis dexmedetomidine Netrin-1 oxygen-glucose deprivation endoplasmic reticulum stress |
| Language | English |
| License | Copyright © 2021 Yin, Li, Ren, Li, Wang, Wang and Zuo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c493t-53f5b5b7388afecb03f0606cb78d332c7f36247756a5a082a9e651fe30e428d93 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 This article was submitted to Neuropharmacology, a section of the journal Frontiers in Neuroscience Reviewed by: Jaeseok Han, Soonchunhyang University, South Korea; Nahid Aboutaleb, Iran University of Medical Sciences, Iran Edited by: Ahmad Reza Dehpour, Tehran University of Medical Sciences, Iran |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fnins.2021.641345 |
| PMID | 33584197 |
| PQID | 2482315045 |
| PQPubID | 4424402 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_100edc714260420b9f39ce3251d1a022 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7876398 proquest_miscellaneous_2489606662 proquest_journals_2482315045 pubmed_primary_33584197 crossref_citationtrail_10_3389_fnins_2021_641345 crossref_primary_10_3389_fnins_2021_641345 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-01-28 |
| PublicationDateYYYYMMDD | 2021-01-28 |
| PublicationDate_xml | – month: 01 year: 2021 text: 2021-01-28 day: 28 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland – name: Lausanne |
| PublicationTitle | Frontiers in neuroscience |
| PublicationTitleAlternate | Front Neurosci |
| PublicationYear | 2021 |
| Publisher | Frontiers Research Foundation Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Research Foundation – name: Frontiers Media S.A |
| References | Stinear (B23) 2020; 19 Wang (B27) 2016; 84 Mirski (B15) 1994; 81 Wu (B30) 2017; 54 Zhang (B35) 2019; 110 Terzi (B25) 2020; 11 Jiwon (B8) 2018; 43 Komotar (B10) 2007; 2 Gissel (B5) 1997; 69 Cai (B3) 2020; 34 Ouyang (B18) 2012; 45 Yu (B33) 2018; 15 Poustchi (B21) 2020; 12 Wang (B29) 2010; 26 Zhu (B36) 2019; 42 Ahn (B1) 2020 Wang (B28) 2006; 79 Meyers (B14) 2019; 11 Nam (B16) 2017; 40 Ji (B7) 2013; 127 Marchi (B13) 2018; 69 Qiu (B22) 2017; 8 Chen (B4) 2020; 11 Lee (B12) 2011; 23 Katsarou (B9) 2011; 1813 Su (B24) 2016; 388 Zhai (B34) 2019; 11 Wu (B31) 2008; 156 Yu (B32) 2017; 11 Gu (B6) 2017; 61 Broughton (B2) 2009; 40 Pang (B19) 2020; 183 Peng (B20) 2019; 13 Oda (B17) 2007; 105 Turan (B26) 2020; 396 Kuhmonen (B11) 2001; 108 |
| References_xml | – volume: 54 start-page: 6970 year: 2017 ident: B30 article-title: Nuclear accumulation of histone deacetylase 4 (HDAC4) exerts neurotoxicity in models of Parkinson’s disease. publication-title: Mol. Neurobiol. doi: 10.1007/s12035-016-0199-2 – volume: 34 year: 2020 ident: B3 article-title: Neuroserpin extends the time window of tPA thrombolysis in a rat model of middle cerebral artery occlusion. publication-title: J. Biomech. Mol. Toxicol. – volume: 11 start-page: 1055 year: 2019 ident: B14 article-title: Current endovascular strategies for posterior circulation large vessel occlusion stroke: report of the society of neurointerventional surgery standards and guidelines committee. publication-title: J. Neurointerv. Surg. doi: 10.1136/neurintsurg-2019-014873 – volume: 11 start-page: 1 year: 2020 ident: B25 article-title: Neuronal NADPH oxidase 2 regulates growth cone guidance downstream of slit2/robo2. publication-title: Dev. Neurobiol. doi: 10.1002/dneu.22791 – volume: 15 year: 2018 ident: B33 article-title: Ca-dependent endoplasmic reticulum stress correlation with astrogliosis involves upregulation of KCa3.1 and inhibition of AKT/mTOR signaling. publication-title: J. Neuroinflammation doi: 10.1186/s12974-018-1351-x – volume: 108 start-page: 261 year: 2001 ident: B11 article-title: Effects of dexmedetomidine after transient and permanent occlusion of the middle cerebral artery in the rat. publication-title: J. Neural. Transm. doi: 10.1007/s007020170071 – volume: 45 start-page: 555 year: 2012 ident: B18 article-title: miR-181 regulates GRP78 and influences outcome from cerebral ischemia in vitro and in vivo. publication-title: Neurobiol. Dis. doi: 10.1016/j.nbd.2011.09.012 – volume: 388 start-page: 1893 year: 2016 ident: B24 article-title: Dexmedetomidine for prevention of delirium in elderly patients after non-cardiac surgery: a randomised, double-blind, placebo-controlled trial. publication-title: Lancent doi: 10.1016/s0140-6736(16)30580-3 – volume: 156 start-page: 475 year: 2008 ident: B31 article-title: Netrin-1 attenuates ischemic stroke-induced apoptosis. publication-title: Neuroscience doi: 10.1016/j.neuroscience.2008.08.015 – volume: 79 start-page: 1839 year: 2006 ident: B28 article-title: Preconditioning-induced activation of ERK5 is dependent on moderate Ca2+ influx via NMDA receptors and contributes to ischemic tolerance in the hippocampal CA1 region of rats. publication-title: Life Sci. doi: 10.1016/j.lfs.2006.06.041 – volume: 127 start-page: 1576 year: 2013 ident: B7 article-title: Perioperative dexmedetomidine improves outcomes of cardiac surgery. publication-title: Circulation doi: 10.1161/circulationaha.112.000936 – volume: 81 start-page: 1422 year: 1994 ident: B15 article-title: Dexmedetomidine decreases seizure threshold in a rat model of experimental generalized epilepsy. publication-title: Anestheisology doi: 10.1097/00000542-199412000-00017 – volume: 69 start-page: 62 year: 2018 ident: B13 article-title: Mitochondrial and endoplasmic reticulum calcium homeostasis and cell death. publication-title: Cell Calcium doi: 10.1016/j.ceca.2017.05.003 – volume: 105 start-page: 1272 year: 2007 ident: B17 article-title: The effect of dexmedetomidine on electrocorticography in patients with temporal lobe epilepsy under sevoflurane anesthesia. publication-title: Anesth. Analg. doi: 10.1213/01.ane.0000281075.77316.98 – volume: 11 year: 2020 ident: B4 article-title: Arc silence aggravates traumatic neuronal injury via mGluR1-mediated ER stress and necroptosis. publication-title: Cell Death Dis. – volume: 61 start-page: 607 year: 2017 ident: B6 article-title: Neuregulin1β effects on brain tissue via ERK5-dependent MAPK pathway in a rat model of cerebral ischemia-reperfusion injury. publication-title: J. Mol. Neurosci. doi: 10.1007/s12031-017-0902-4 – year: 2020 ident: B1 article-title: BDNF and Netrin-1 repression by C/EBPβ in the gut triggers Parkinson’s disease pathologies, associated with constipation and motor dysfunctions. publication-title: Prog. Neurobiol. doi: 10.1016/j.pneurobio.2020.101905 – volume: 2 start-page: 2345 year: 2007 ident: B10 article-title: Neurologic assessment of somatosensory dysfunction following an experimental rodent model of cerebral ischemia. publication-title: Nat. Protoc. doi: 10.1038/nprot.2007.359 – volume: 40 start-page: 457 year: 2017 ident: B16 article-title: CHOP deficiency ameliorates ERK5 inhibition-mediated exacerbation of streptozotocin-induced hyperglycemia and pancreatic β-Cell apoptosis. publication-title: Mol. Cell doi: 10.14348/molcells.2017.2296 – volume: 12 year: 2020 ident: B21 article-title: Combination therapy of killing diseases by injectable hydrogels: from concept to medical applications. publication-title: Adv. Healthc. Mater. doi: 10.1002/adhm.202001571 – volume: 11 year: 2017 ident: B32 article-title: Netrin-1 ameliorates blood-brain barrier impairment secondary to ischemic stroke via the activation of PI3K pathway. publication-title: Front. Neurosci. doi: 10.3389/fnins.2017.00700 – volume: 40 start-page: e331 year: 2009 ident: B2 article-title: Apoptotic mechanisms after cerebral ischemia. publication-title: Stroke doi: 10.1161/STROKEAHA.108.531632 – volume: 69 start-page: 2538 year: 1997 ident: B5 article-title: Temporal analysis of changes in neuronal c-fos mRNA levels induced by depletion of endoplasmic reticulum calcium stores: effect of clamping cytoplasmic calcium activity at resting levels. publication-title: J. Neurochem. doi: 10.1046/j.1471-4159.1997.69062538.x – volume: 26 start-page: 437 year: 2010 ident: B29 article-title: Duplicate preconditioning with sevoflurane in vitro improves neuroprotection in rat brain via activating the extracellular signal-regulated protein kinase. publication-title: Neurosci. Bull. doi: 10.1007/s12264-010-6024-4 – volume: 13 year: 2019 ident: B20 article-title: Isoflurane post-conditioning ameliorates cerebral ischemia/reperfusion injury by enhancing angiogenesis through activating the Shh/Gli signaling pathway in rats. publication-title: Front. Neurosci. doi: 10.3389/fnins.2019.00321 – volume: 1813 start-page: 1854 year: 2011 ident: B9 article-title: MEK5/ERK5/mef2: a novel signaling pathway affected by hepatitis C virus non-enveloped capsid-like particles. publication-title: Biochem. Biophys. Acta doi: 10.1016/j.bbamcr.2011.06.015 – volume: 183 year: 2020 ident: B19 article-title: AMPK upregulates K2.3 channels and ameliorates endothelial dysfunction in diet-induced obese mice. publication-title: Biochem. Pharmacol. doi: 10.1016/j.bcp.2020.114337 – volume: 43 start-page: 593 year: 2018 ident: B8 article-title: Quality control in the endoplasmic reticulum: crosstalk between ERAD and UPR pathways. publication-title: Trends Biochem. Sci. doi: 10.1016/j.tibs.2018.06.005 – volume: 42 start-page: 2181 year: 2019 ident: B36 article-title: Role of JNK signaling pathway in dexmedetomidine post-conditioning-induced reduction of the inflammatory response and autophagy effect of focal cerebral ischemia reperfusion injury in rats. publication-title: Inflammation doi: 10.1007/s10753-019-01082-2 – volume: 23 start-page: 1100 year: 2011 ident: B12 article-title: HB-EGF induces cardiomyocyte hypertrophy via an ERK5-MEF2A-COX2 signaling pathway. publication-title: Cell Signal. doi: 10.1016/j.cellsig.2011.01.006 – volume: 84 start-page: 535 year: 2016 ident: B27 article-title: Effects of activin a and its downstream ERK1/2 in oxygen and glucose deprivation after isoflurane-induced postconditioning. publication-title: Biomed. Pharmacother. doi: 10.1016/j.biopha.2016.09.075 – volume: 110 start-page: 420 year: 2019 ident: B35 article-title: Wnt/β-catenin signaling pathway contributes to isoflurane postconditioning against cerebral ischemia-reperfusion injury and is possibly related to the transforming growth factorβ1/Smad3 signaling pathway. publication-title: Biomed. Pharmacother. doi: 10.1016/j.biopha.2018.11.143 – volume: 8 year: 2017 ident: B22 article-title: Low dose of apelin-36 attenuates ER stress-associated apoptosis in rats with ischemic stroke. publication-title: Front. Neurol. doi: 10.3389/fneur.2017.00556 – volume: 19 start-page: 348 year: 2020 ident: B23 article-title: Advances and challenges in stroke rehabilitation. publication-title: Lancent Neurol. doi: 10.1016/S1474-4422(19)30415-6 – volume: 11 start-page: 9556 year: 2019 ident: B34 article-title: Dexmedetomidine inhibits neuronal apoptosis by inducing sigma-1 receptor signaling in cerebral ischemia-reperfusion injury. publication-title: Aging doi: 10.18632/aging.102404 – volume: 396 start-page: 177 year: 2020 ident: B26 article-title: Dexmedetomidine for reduction of atrial fibrillation and delirium after cardiac surgery (DECADE): a randomised placebo-controlled trial. publication-title: Lancet doi: 10.1016/s0140-6736(20)30631-0 |
| SSID | ssj0062842 |
| Score | 2.366273 |
| Snippet | The complexity of hard-to-treat diseases such as ischemic stroke strongly undermines the therapeutic potential of available treatment options. Therefore,... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 641345 |
| SubjectTerms | Anesthesia Apoptosis Carotid arteries Cerebral blood flow cerebral ischemia/reperfusion dexmedetomidine Endoplasmic reticulum endoplasmic reticulum stress Experiments Glucose Hippocampus Hypoxia Immunofluorescence Ischemia Kinases Laboratory animals Medical prognosis Microinjection Nervous system Netrin-1 Neuroprotection Neuroscience Oxygen oxygen-glucose deprivation Phosphorylation Proteins Reperfusion RNA-mediated interference Rodents Signal transduction Veins & arteries |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3fb9MwELbQnnhBwPhR2NAhIR6Qwpw4iZPHMlptoE1obNLeItuxtaDVnUaq0T-H_5Q7O61ahOCFlz7Ebuzk7nzf-ZzvGHujKie1c22SVkokOa6AiXLSJdIhfuZG6SzwbJ-clkcX-afL4nKj1BedCYv0wPHFoVVz2xqZEpN6nnFdO1EbK9Att6lCB0SrL_q8VTAV1-ASF90s5jAxBKsPnO88cXNn6fsSV236dmnDCwWy_j8hzN8PSm54nulD9mCAjDCOU33E7ln_mO2OPYbLsyW8hXCIM-yO77KfH-0PvJPFpg69kgXlWzilqlk-SQGNHwPhIAs4j3QCcOyvOt3132Hi2_kNYulZZ-DM9nFfEL6Gb0lAL_FaqFqPrg4QNMLk7HNxcDKZZmP4gijyTi2hn8O4Rwy-QPwKh_aWctLXcIzxs511Ckf6hgJ8wi6mk_PDo2SowpCYvBZ9UghX6EJLUVXKWaO5cByjHqNl1QqRGenQB-ZSFqUqFAIKVduySJ0V3GJo09biKdvxc2-fM3BVWeZWuYyXLqeMJP6a3KWuzEwqpRoxvpJKYwaKcqqUcd1gqEKCbIIgGxJkEwU5Yu_Wf7mJ_Bx_6_yBRL3uSNTa4QIqXDMoXPMvhRuxvZWiNIO94yA5pVMLTmO8XjejpVL6RXk7X4Q-MVzEWzyLerWeiRAIBNNajpjc0ritqW63-O4qsIFL4hSsqxf_49lesvv0umiLKav22E5_u7D7CLp6_SrY1y9xayti priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Nb9QwELWgvXBBQPkILchIiANS2CRO7OSEtiWrFtRVtbRSb5Hj2DSo62y3WcH-HP4pM0426iLUSw6xk1gZe-bNjP2GkPcyNaI0pvLDVDI_Bg3oSyOMLwzg50DJMnI826dTfnwRf71MLvuA222_rXKjE52irhqFMfJRFGPCKgEE8nlx42PVKMyu9iU0HpJdUMEpOF-7h_n0bLbRxRyUr8t3cjwbBOC8y2uCW5aNjK0t8nVH4ScOmhzPM92xTI7A_3-o89_Nk3es0eQJedzDSDru5P6UPND2GdkbW3Ch52v6gbqNnS5ivkf-fNG_4U0ammqwVJpKW9EpVtKyfkhBIYBz7ORDzzuKAXpir-qybm9pbqtmAfh6Xis6020XK6Tf3fkSWq7hnqtkD-aPApCk-exbMjrNJ9GYngGy_CXXtG3ouAVcvgJMS4_0EvPU1_QEfGo9ryV86ScI9Tm5mOTnR8d-X5nBV3HGWj9hJimTUrA0lUarMmAmAE9IlSKtGIuUMGAXYyESLhMJIENmmieh0SzQ4O5UGXtBdmxj9StCTcp5rKWJAm5izFLCVcUmNDxSoRDSI8FGKoXqacuxesZ1Ae4LCrJwgixQkEUnSI98HB5ZdJwd93U-RFEPHZFu291olj-KfvUisTMIXIRI5x9HQZkZlinNABtWoQQU5JGDzUQpeh0AHxlmrEfeDc2wejElI61uVq5P50LCK15282oYCWMADsNMeERszbitoW632PrKMYQL5BnM0tf3D2ufPMIfgQGlKD0gO-1ypd8AxGrLt_06-gvHoCdh priority: 102 providerName: ProQuest |
| Title | Dexmedetomidine and Netrin-1 Combination Therapy Inhibits Endoplasmic Reticulum Stress by Regulating the ERK5/MEF2A Pathway to Attenuate Cerebral Ischemia Injury |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33584197 https://www.proquest.com/docview/2482315045 https://www.proquest.com/docview/2489606662 https://pubmed.ncbi.nlm.nih.gov/PMC7876398 https://doaj.org/article/100edc714260420b9f39ce3251d1a022 |
| Volume | 15 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Bb9MwFLbGJqFdEDBghVEZCXFAypbETpwcEOpGygZqNZVV6i1yEpsFte7oUrH-HP4p7zlptKKKA5ccYseJ8j37fc8v-R4hb2WkRaZ14XiRZA6HFdCRWmhHaODPbi4z3-psD4bh-Zh_mQSTHbIub9W8wNutoR3Wkxovpsd3P1cfYcJ_wIgT_O2JNqVB5W3fOw5hTebBA7IHjkngPB3wNqkQwkpsk58h_igETL1Ocm4fYp88ZAycs4dqUPc8lhX238ZG__6o8p6X6j8mjxp6SXu1PTwhO8o8JQc9A6H1bEXfUfvBp91JPyC_P6k7GElBUwkeTFFpCjrEClvG8SgsFBA0W9zoVS09QC_MdZmV1S1NTDG_Ad49K3M6UlW9h0i_2f9OaLaCc7bCPbhFCgSTJqOvwckg6fs9egmM85dc0WpOexXw9SVwXXqmFpi_ntILAETNSgl3-gFgPyPjfnJ1du40FRucnMescgKmgyzIBIsiqVWeuUy7ECHlmYgKxvxcaPCXXIgglIEE8iFjFQaeVsxVEAYVMXtOds3cqENCdRSGXEntu6HmmL2EY861p0M_94SQHeKuUUnzRs4cq2pMUwhrENPUYpoipmmNaYe8by-5qbU8_tX5FKFuO6IMtz0xX3xPm1mNgs8AuPBQ5p_7bhZrFueKAWcsPAnsqEOO1oaSrk079TmmXgMX7_GmbYZZjakaadR8afvUoSUM8aK2q_ZJ1nbZIWLD4jYedbPFlNdWOVyg_mAcvfzvK1-RfXxHuAflR0dkt1os1WtgZVXWJXunyfBy1LW7GnD8PPG6dv79Ab_4OtU |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwELem7gFeEDD-FAYYCXhACkviJE4eEOq2Vi1dq6l00t6Ck9hd0OqULtXox-EL8Bm5c5JqRWhve8lD7CRW7vy73_nsO0LeiVDxRKnMckLBLA8Q0BKKK4sr4M92KhLX5NkejYP-mff13D_fIX-aszC4rbLBRAPUWZHiGvmB62HAygcG8mXx08KqURhdbUpoVGoxlOtrcNmuPg-OQb7vXbfXnR71rbqqgJV6ESstnyk_8RPOwlAomSY2Uzaw-DThYcaYm3IFmO5x7gfCF2AgRSQD31GS2RKoeobJlwDydz0GrkyL7B52x6eTBvsDAHsTXw3wLBI4A1UcFdzA6EDpXGN-cNf5FIDlwPNTNyyhKRjwP5b772bNG9av95A8qGkr7VR69ojsSP2Y7HU0uOzzNf1AzUZSs0K_R34fy1_wJglNOVhGSYXO6Bgrd2nLoQBA4IwbfaDTKqUBHeiLPMnLK9rVWbEAPj_PUzqRZbU2Sb-Z8yw0WcO9mSk3pmcUiCvtTob-wajbczv0FJjstVjTsqCdEvyAFXBoeiSXGBe_pAPw4eU8F_ClH6BET8jZncjsKWnpQsvnhKowCDwplGsHysOoKFxTTzkqcFOHc9EmdiOVOK3TpGO1jssY3CUUZGwEGaMg40qQbfJx88iiyhFyW-dDFPWmI6b3NjeK5Syu0QITSYPAuYPlAzzXTiLFolQy4KKZI4B1tcl-oyhxjTnwkc0MaZO3m2ZACwwBCS2LlelTuazwimeVXm1GwhiQUSfibcK3NG5rqNstOr8wGck55jWMwhe3D-sNudefjk7ik8F4-JLcx5-Ci1luuE9a5XIlXwG9K5PX9Zyi5PtdT-O_a3tjXg |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwELemTkK8IGD8KQwwEvCAFJrESZw8INStrVbKqqps0t4yJ7G7oNUpXarRj8PX4NNx5yTVitDe9pKH2Ems3Pnu9_PZd4S8E6HiiVKZ5YSCWR5YQEsoriyuAD_bqUhck2f7eBwcnXpfz_yzHfKnOQuD2yobm2gMdVakuEbecT0MWPmAQDqq3hYx6Q2-LH5aWEEKI61NOY1KRUZyfQ307erzsAeyfu-6g_7J4ZFVVxiwUi9ipeUz5Sd-wlkYCiXTxGbKBkSfJjzMGHNTrsC-e5z7gfAFOEsRycB3lGS2BNieYSImMP-7HFiR3SK7B_3xZNr4gQAMv4m1BnguCYhBFVMFShh1lM415gp3nU8BeBE8S3XDK5riAf9DvP9u3LzhCQcPyYMawtJupXOPyI7Uj8leVwN9n6_pB2o2lZrV-j3yuyd_wZskNOXgJSUVOqNjrOKlLYeCMQJibnSDnlTpDehQX-RJXl7Rvs6KBWD7eZ7SqSyrdUr63Zxtocka7s1M6TE9owBiaX868jvH_YHbpRNAtddiTcuCdkvgBCvA0_RQLjFGfkmHwOflPBfwpR-gUE_I6Z3I7Clp6ULL54SqMAg8KZRrB8rDCClcU085KnBTh3PRJnYjlTitU6Zj5Y7LGKgTCjI2goxRkHElyDb5uHlkUeULua3zAYp60xFTfZsbxXIW15YDk0qDwLmDpQQ8104ixaJUMsClmSMAgbXJfqMocW1_4COb2dImbzfNYDkwHCS0LFamT0Vf4RXPKr3ajIQxAKZOxNuEb2nc1lC3W3R-YbKTc8xxGIUvbh_WG3IPpm_8bTgevST38Z_gupYb7pNWuVzJV4D0yuR1PaUoOb_rWfwX-xpnkw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Dexmedetomidine+and+Netrin-1+Combination+Therapy+Inhibits+Endoplasmic+Reticulum+Stress+by+Regulating+the+ERK5%2FMEF2A+Pathway+to+Attenuate+Cerebral+Ischemia+Injury&rft.jtitle=Frontiers+in+neuroscience&rft.au=Yin%2C+Jiang-Wen&rft.au=Li%2C+Jia&rft.au=Ren%2C+Yi-Min&rft.au=Li%2C+Yan&rft.date=2021-01-28&rft.pub=Frontiers+Media+S.A&rft.issn=1662-4548&rft.eissn=1662-453X&rft.volume=15&rft_id=info:doi/10.3389%2Ffnins.2021.641345&rft_id=info%3Apmid%2F33584197&rft.externalDocID=PMC7876398 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1662-453X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1662-453X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1662-453X&client=summon |